Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: The ALLIANCE Study

Antiviral Therapy

Volumn 11, Issue 4, 2006, Pages 409-419

  Dwyer, Dominic E ^a   Workman, Cassy ^b   Hales, Gillian ^c   Amin, Janaki ^c   Cooper, David ^c   Miller, John ^d   Emery, Seon ^c  

^a WESTMEAD HOSPITAL   (Australia)

^b AIDS Research Initiative   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d Roche Products Pty Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; ENFUVIRTIDE; LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIPRANAVIR;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CD4+ T LYMPHOCYTE; CELL COUNT; CONTROLLED STUDY; DIARRHEA; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; HYPERSENSITIVITY REACTION; LACTIC ACIDEMIA; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33745790291     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Mocroft A, Vella S, Benfield TL, et al. Changing paterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730.
2. Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, Bolgnesi D. Enfuvirtide: the first therapy to inhibit the entry of HFV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 2004; 3:215-225.
3. Kilby JM, Lalezari JP, Eron JJ, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002; 18:685-693.
4. Lalezari JP, Eron JJ, Carlson M, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS Res Hum Retroviruses 2003; 17:691-698.
5. Hanna SL, Yang C, Owen SM, Lal RB. Resistance mutation in HIV entry inhibitors. AIDS 2002; 16:1603-1608.
6. Miller MD & Hazuda DJ. HIV resistance to the fusion inhibitor enfuvirtide: Mechanisms and clinical implications. Drug Resistance Updates 2004; 7:89-95.
7. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896-1905.
8. Sista PR, Melby T, Davison D, et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 2004; 18:1787-1794.
9. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-2185.
10. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-2195.
11. Clotet B, Raffi F, Cooper D, et al. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: Consensus recommendations. AIDS 2004; 18:1137-1146.
12. Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005; 40:404-412.
13. Cohen CJ, Clumeck N, Molina JM, et al. Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen. J Acquir Immune Defic Syndr 2004; 37:1140-1146.
14. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. J Am Med Assoc 2002; 288:207-215.
15. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. J Am Med Assoc 2004; 292:191-201.
16. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5:41-48.
17. Smith DE, Hudson J, Martin A, et al. Centralized assessment of dual-energy X-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophy. HIV Clin Trials 2003; 4:45-49.
18. Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol 2004; 78:4628-4637.
19. Reeves JD, Lee F-H, Miamidian JL, Jabara CB, Juntilla MM, Doms RW. Enfuvirtide resistance mutations: Impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 2005; 79:4991-4999.
20. Lalezari JP, Bellos NC, Sathasivam K, et al. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen. J Infect Dis 2005; 191:1155-1163.